Share Price and Basic Stock Data
Last Updated: November 14, 2025, 12:00 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fabino Enterprises Ltd operates within the pharmaceuticals industry, reporting a current market capitalization of ₹4.83 Cr and a share price of ₹23.00. The company has demonstrated fluctuating revenue trends over recent quarters. Sales recorded in March 2021 stood at ₹2.38 Cr, followed by a decline to ₹1.04 Cr in September 2022. However, the revenue rebounded to ₹2.32 Cr in March 2023, before dropping to ₹0.94 Cr in September 2023. Notably, projected sales for March 2025 are anticipated to rise significantly to ₹13.78 Cr, indicating a potential recovery trajectory. The annual sales figures reveal a similar pattern, with ₹3.36 Cr in March 2023 and a forecast of ₹18.00 Cr for March 2025. This suggests that while Fabino has faced challenges, there is an expectation of substantial growth in the near future, driven by strategic initiatives or product launches.
Profitability and Efficiency Metrics
The profitability metrics of Fabino Enterprises reveal a mixed performance. The company reported a net profit margin of 0.33% for March 2025, up from 0.16% in March 2024, indicating slight improvement, albeit still below industry averages. Operating profit margins (OPM) have consistently been low, recorded at 0.94% for March 2025, reflecting challenges in managing operational costs effectively. The interest coverage ratio stood at 3.08x, suggesting that the company can comfortably meet its interest obligations, a positive sign amidst its financial struggles. Additionally, the cash conversion cycle (CCC) is reported at 51.93 days, which is relatively efficient compared to typical industry ranges. However, the return on equity (ROE) at 3.08% and return on capital employed (ROCE) at 7.16% signal inefficiencies that the company must address to enhance shareholder value.
Balance Sheet Strength and Financial Ratios
Fabino Enterprises maintains a balance sheet with no reported borrowings, which is a considerable strength, as it avoids interest liabilities that could burden profitability. The company has a price-to-book value (P/BV) ratio of 1.22x, indicating that the market values the company slightly above its book value, reflecting moderate investor confidence. However, the absence of reserves suggests limited financial cushioning for unforeseen challenges, which could pose risks in volatile market conditions. The current ratio is reported at 1.46x, indicating sufficient liquidity to cover short-term liabilities, while the quick ratio of 1.36x further supports this liquidity position. The company’s asset turnover ratio of 1.09% illustrates that it is generating revenue effectively relative to its asset base, although this figure is lower than the industry averages, indicating room for improvement in asset efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fabino Enterprises shows a stable structure, with promoters holding 56.82% and the public holding 43.18%. This indicates a strong promoter commitment, which can instill confidence among investors. The number of shareholders has decreased from 195 in March 2022 to 129 in March 2025, which could suggest consolidation or a lack of new investor interest. The stability in promoter holdings, coupled with the public’s slight decline, may reflect cautious investor sentiment amidst fluctuating performance metrics. Additionally, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate a perception of risk associated with the company’s financial performance. This lack of institutional backing could hinder the stock’s liquidity and overall market perception, necessitating strategic efforts to attract institutional interest.
Outlook, Risks, and Final Insight
Fabino Enterprises faces a mixed outlook characterized by both growth potential and inherent risks. On one hand, the anticipated increase in revenues and slight improvements in profitability metrics suggest a path toward recovery. However, the company must address its low operating margins and efficiency ratios to unlock greater shareholder value. Risks include the lack of reserves, which could limit financial flexibility in downturns, and the declining shareholder base, which may affect market confidence. Additionally, the absence of institutional investment could hinder growth prospects. To enhance its market position, Fabino may need to focus on operational efficiency, strategic partnerships, and innovative product development. If these strategies are successfully implemented, the company could experience a turnaround, capturing both investor interest and market share in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fabino Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.38 | 2.05 | 2.15 | 1.04 | 2.32 | 0.94 | 5.14 | 4.25 | 13.78 |
| Expenses | 2.15 | 2.11 | 2.00 | 1.03 | 2.30 | 0.87 | 5.10 | 4.21 | 13.65 |
| Operating Profit | 0.23 | -0.06 | 0.15 | 0.01 | 0.02 | 0.07 | 0.04 | 0.04 | 0.13 |
| OPM % | 9.66% | -2.93% | 6.98% | 0.96% | 0.86% | 7.45% | 0.78% | 0.94% | 0.94% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.07 |
| Depreciation | 0.02 | 0.00 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 |
| Profit before tax | 0.21 | -0.05 | 0.12 | 0.01 | 0.00 | 0.06 | 0.01 | 0.07 | 0.20 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 33.33% | 0.00% | 28.57% | 55.00% | |
| Net Profit | 0.21 | -0.05 | 0.10 | 0.01 | 0.00 | 0.05 | 0.00 | 0.05 | 0.09 |
| EPS in Rs | 1.75 | -0.42 | 0.48 | 0.05 | 0.00 | 0.24 | 0.00 | 0.24 | 0.43 |
Last Updated: May 31, 2025, 6:05 am
Below is a detailed analysis of the quarterly data for Fabino Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 13.78 Cr.. The value appears strong and on an upward trend. It has increased from 4.25 Cr. (Sep 2024) to 13.78 Cr., marking an increase of 9.53 Cr..
- For Expenses, as of Mar 2025, the value is 13.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.21 Cr. (Sep 2024) to 13.65 Cr., marking an increase of 9.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Sep 2024) to 0.13 Cr., marking an increase of 0.09 Cr..
- For OPM %, as of Mar 2025, the value is 0.94%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.94%.
- For Other Income, as of Mar 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Sep 2024) to 0.18 Cr., marking an increase of 0.07 Cr..
- For Interest, as of Mar 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 0.20 Cr., marking an increase of 0.13 Cr..
- For Tax %, as of Mar 2025, the value is 55.00%. The value appears to be increasing, which may not be favorable. It has increased from 28.57% (Sep 2024) to 55.00%, marking an increase of 26.43%.
- For Net Profit, as of Mar 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.05 Cr. (Sep 2024) to 0.09 Cr., marking an increase of 0.04 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.43. The value appears strong and on an upward trend. It has increased from 0.24 (Sep 2024) to 0.43, marking an increase of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:22 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.00 | 14.46 |
| Expenses | 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.90 | 17.83 | 14.59 |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 | 0.17 | -0.13 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.83% | 0.94% | -0.90% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.29 | 0.33 |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 | 0.15 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.09 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 | -0.04 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | ||
| Net Profit | 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 | -0.16 |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -57.14% | 66.67% | -80.00% | 400.00% | 160.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 123.81% | -146.67% | 480.00% | -240.00% |
Fabino Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 63% |
| TTM: | 200% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 38% |
| TTM: | 160% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:30 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 177.43 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 152.06 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 51.93 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.21 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Diluted EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Cash EPS (Rs.) | 0.67 | 0.37 | 0.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Revenue From Operations / Share (Rs.) | 85.89 | 100.39 | 16.00 |
| PBDIT / Share (Rs.) | 1.90 | 0.62 | 0.22 |
| PBIT / Share (Rs.) | 1.51 | 0.41 | 0.07 |
| PBT / Share (Rs.) | 0.89 | 0.23 | 0.05 |
| Net Profit / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| NP After MI And SOA / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| PBDIT Margin (%) | 2.21 | 0.62 | 1.42 |
| PBIT Margin (%) | 1.76 | 0.41 | 0.47 |
| PBT Margin (%) | 1.04 | 0.23 | 0.36 |
| Net Profit Margin (%) | 0.33 | 0.16 | 0.32 |
| NP After MI And SOA Margin (%) | 0.33 | 0.16 | 0.32 |
| Return on Networth / Equity (%) | 1.45 | 0.86 | 0.26 |
| Return on Capital Employeed (%) | 5.29 | 1.59 | 0.35 |
| Return On Assets (%) | 0.34 | 0.23 | 0.21 |
| Long Term Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Total Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Asset Turnover Ratio (%) | 1.09 | 2.07 | 0.00 |
| Current Ratio (X) | 1.46 | 1.51 | 10.73 |
| Quick Ratio (X) | 1.36 | 1.37 | 8.07 |
| Inventory Turnover Ratio (X) | 14.21 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.08 | 3.48 | 12.01 |
| Interest Coverage Ratio (Post Tax) (X) | 1.47 | 1.95 | 3.72 |
| Enterprise Value (Cr.) | 6.69 | 9.52 | 6.46 |
| EV / Net Operating Revenue (X) | 0.37 | 0.45 | 1.92 |
| EV / EBITDA (X) | 16.78 | 72.62 | 135.37 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.39 | 1.87 |
| Price / BV (X) | 1.22 | 2.01 | 1.53 |
| Price / Net Operating Revenue (X) | 0.28 | 0.39 | 1.88 |
| EarningsYield | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Fabino Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.67, marking an increase of 0.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.89. It has decreased from 100.39 (Mar 24) to 85.89, marking a decrease of 14.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 2. It has increased from 0.62 (Mar 24) to 1.90, marking an increase of 1.28.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.41 (Mar 24) to 1.51, marking an increase of 1.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.89. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.89, marking an increase of 0.66.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For PBDIT Margin (%), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 10. It has increased from 0.62 (Mar 24) to 2.21, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 1.76. This value is below the healthy minimum of 10. It has increased from 0.41 (Mar 24) to 1.76, marking an increase of 1.35.
- For PBT Margin (%), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 10. It has increased from 0.23 (Mar 24) to 1.04, marking an increase of 0.81.
- For Net Profit Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 5. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 8. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has increased from 0.86 (Mar 24) to 1.45, marking an increase of 0.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.29. This value is below the healthy minimum of 10. It has increased from 1.59 (Mar 24) to 5.29, marking an increase of 3.70.
- For Return On Assets (%), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.23 (Mar 24) to 0.34, marking an increase of 0.11.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has decreased from 2.07 (Mar 24) to 1.09, marking a decrease of 0.98.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.51 (Mar 24) to 1.46, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.36, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.21, marking an increase of 14.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 3.08, marking a decrease of 0.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to 1.47, marking a decrease of 0.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.69. It has decreased from 9.52 (Mar 24) to 6.69, marking a decrease of 2.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.45 (Mar 24) to 0.37, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 16.78. This value exceeds the healthy maximum of 15. It has decreased from 72.62 (Mar 24) to 16.78, marking a decrease of 55.84.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.22, marking a decrease of 0.79.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fabino Enterprises Ltd:
- Net Profit Margin: 0.33%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.29% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.47
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.36
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.33%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Jeevan Vihar Extension Near, Shubham Garden, Sonipat Haryana 131001 | info@fabinolife.com www.fabinolife.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Jain | Managing Director |
| Mr. Arihant Jain | Non Executive Director |
| Mr. Sumit Malik | Non Executive Director |
| Mr. Kuldeep Singh Solanki | Independent Director |
| Mrs. Tesu Alakh | Independent Director |
| Mrs. Vandana Jain | Additional Director |

